Accelerated Chemotherapy for Advanced Ovarian Cancer
Author Information
Author(s): P Pronzato, G Bertelli, A Viganil, F Vaira
Primary Institution: Ospedale S. Andrea, La Spezia, Italy; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Hypothesis
Can increasing the dose intensity of the PEC chemotherapy regimen improve outcomes in advanced ovarian cancer?
Conclusion
The study shows that an accelerated PEC regimen is feasible and can achieve high dose intensity without severe toxicity.
Supporting Evidence
- 21 out of 22 patients completed six cycles of treatment.
- 9 out of 16 evaluable patients achieved a complete clinical response.
- 90.5% of patients received at least 85% of the planned dose intensity.
Takeaway
Doctors tried giving more chemotherapy to women with advanced ovarian cancer more often, and it worked well without making them very sick.
Methodology
Patients received six cycles of PEC chemotherapy every 14 days with G-CSF support.
Limitations
The study does not conclusively determine the clinical benefits of increased dose intensity.
Participant Demographics
Median age was 51 years, with FIGO stages ranging from IIIA to IV.
Statistical Information
Confidence Interval
95% confidence limits, 77.9% - 100%
Want to read the original?
Access the complete publication on the publisher's website